Previous Close | 68.05 |
Open | 68.35 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 1,040.00 |
Expire Date | 2025-09-19 |
Day's Range | 68.05 - 68.35 |
Contract Range | N/A |
Volume | |
Open Interest | 11 |
Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed them from its shortage list — signaling the pharmaceutical giant's ability to now meet market demand. In contrast, shares of competitor Hims & Hers Health (HIMS) are plummeting following this news. Market Domination hosts Madison Mills and Josh Schafer discuss the news and Citi's take on it. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Angel Smith
Stock picking is the hallmark of top mutual fund T. Rowe Price U.S. Equity Research Fund (PRCOX). But what makes this top stock mutual fund unique is that it's not the fund managers who pick the stocks that make it into the portfolio.
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), Mastercard Incorporated (MA) and The Procter & Gamble Company (PG), as well a micro-cap stock Vaso Corporation (VASO).